InvestSMART

Lumos Diagnostics Holdings Limited (ASX:LDX)

ALERT: Price-sensitive ASX Announcement for LDX
Current share price for LDX : $0.105 -0.02 (-16%)+
Announcement
Release
18 May 2026 11:42AM
Price at Release
$0.125
Full Release
download
Summary
Lumos Diagnostics Holdings Limited has provided an update on the commercialization and reimbursement progress of its FebriDx® test in the U.S. market after receiving FDA CLIA waiver clearance. The company is working on expanding its market presence ahead of the 2026/27 U.S. flu season by building awareness, onboarding customers, and ensuring reimbursement pathways in CLIA-waived settings. FebriDx® is now used routinely across 44 WellStreet urgent care clinics, and additional pilot sites are being evaluated favorably. The reimbursement progress shows that over 90% of claims are being paid, with payments surpassing the Medicare fee schedule rate, indicating successful initial commercialization. The company aims to support customers with reimbursement education as they prepare for the flu season.
Key Points
  • FebriDx® received FDA CLIA waiver clearance.
  • Commercial foundations are being built for the 2026/27 U.S. flu season.
  • FebriDx® is in use at 44 WellStreet urgent care clinics.
  • Over 90% of reimbursement claims are being paid.
  • Average payment per test is above the Medicare fee schedule rate.
  • Support for customer reimbursement education is ongoing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.